Before visiting, please review our current visitor policies and COVID-19 information.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

AFT-50

Trial Overview

Official Title

A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Study Purpose

To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.

Diagnosis

Patients who have endometrial cancer that has spread to other parts of the body and/or the disease returned or got worse during or after treatment with chemotherapy.

Eligibility

Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Cohort 1: Atezolizumab plus Bevacizumab

Cohort 2: Atezolizumab plus Ipatasertib

Cohort 3: Atezolizumab plus Talazoparib

Cohort 4: Atezolizumab plus Trastuzumab emtamsine

Cohort 5: Atezolizumab plus Tiragolumab

The duration of this is study is 48 months.

After completion of study treatment, the doctor will continue to follow up with the patient every 3 months.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase IB
Methodist Health System Trial Code
AFT-50
Related Specialties